Viridian Therapeutics Inc (VRDN)

2026-05-15T12:28:02.000Z - 1 day ago

Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI

May 14, 2026, 11:43 AM EDT - 2 days ago

Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting

2026-05-13T18:58:41.000Z - 3 days ago

Viridian Therapeutics price target lowered to $39 from $48 at Stifel

2026-05-07T11:24:55.000Z - 9 days ago

Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00

2026-05-07T06:49:01.000Z - 9 days ago

Viridian Therapeutics price target raised to $34 from $30 at RBC Capital

May 6, 2026, 11:13 PM EDT - 9 days ago

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

May 5, 2026, 4:05 PM EDT - 11 days ago

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

May 5, 2026, 8:00 AM EDT - 11 days ago

Viridian Therapeutics Transcript: Study result

2026-05-05T11:38:18.000Z - 11 days ago

Viridian announces REVEAL-2 phase 3 study met primary endpoint

2026-05-05T11:26:55.000Z - 11 days ago

Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)

May 5, 2026, 7:05 AM EDT - 11 days ago

Viridian eye disease drug benefits chronic patients in late-stage trial

May 5, 2026, 7:01 AM EDT - 11 days ago

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 5, 2026, 7:00 AM EDT - 11 days ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

2026-04-21T15:48:24.000Z - 25 days ago

Viridian Therapeutics price target lowered to $33 from $36 at Truist

2026-04-13T13:57:38.000Z - 4 weeks ago

Viridian Therapeutics price target lowered to $24 from $32 at Evercore ISI

2026-04-08T12:32:05.000Z - 5 weeks ago

Viridian Therapeutics price target lowered to $36 from $40 at Truist

AMGN

2026-04-08T11:48:42.000Z - 5 weeks ago

Viridian Therapeutics price target lowered to $31 from $37 at Wedbush

AMGN

2026-04-07T13:56:27.000Z - 5 weeks ago

Viridian Therapeutics price target lowered to $30 from $42 at RBC Capital

2026-04-07T11:50:43.000Z - 5 weeks ago

Viridian Therapeutics removed from Best Ideas List at Wedbush

2026-04-06T17:30:48.000Z - 5 weeks ago

Leerink sees weakness in Viridian Therapeutics shares as ‘overdone’

AMGN

Apr 6, 2026, 12:10 PM EDT - 5 weeks ago

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

AMGN

2026-04-06T14:46:07.000Z - 5 weeks ago

Viridian sinks after Amgen thyroid eye disease study hits endpoints

2026-04-02T11:53:35.000Z - 6 weeks ago

Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list

AMGN

2026-03-31T11:58:41.000Z - 6 weeks ago

Viridian Therapeutics price target lowered to $37 from $44 at Wedbush

2026-03-31T10:52:48.000Z - 6 weeks ago

Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

Viridian Therapeutics Transcript: Study result

Mar 30, 2026, 7:01 AM EDT - 6 weeks ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Mar 9, 2026, 8:00 AM EDT - 2 months ago

Viridian Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 10:30 AM EST - 2 months ago

Viridian Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 7:01 AM EST - 2 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Jan 8, 2026, 4:01 PM EST - 4 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2026, 7:01 AM EST - 4 months ago

Viridian Therapeutics Prepares for Transformational 2026

Dec 22, 2025, 7:00 AM EST - 5 months ago

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Dec 4, 2025, 9:35 AM EST - 5 months ago

Viridian Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 19, 2025, 3:00 AM EST - 6 months ago

Viridian Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 9:20 AM EST - 6 months ago

Viridian Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 7:01 AM EST - 6 months ago

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 3, 2025, 7:01 AM EST - 6 months ago

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Oct 21, 2025, 11:24 PM EDT - 7 months ago

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Oct 21, 2025, 4:01 PM EDT - 7 months ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Oct 20, 2025, 7:30 AM EDT - 7 months ago

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Sep 15, 2025, 7:01 AM EDT - 8 months ago

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Aug 6, 2025, 6:30 AM EDT - 10 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:00 AM EDT - 10 months ago

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Jul 3, 2025, 7:00 AM EDT - 11 months ago

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:35 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 20, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 7, 2025, 4:15 PM EDT - 1 year ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 6, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Apr 7, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 9:10 AM EST - 1 year ago

Viridian Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 8, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Dec 16, 2024, 7:10 AM EST - 1 year ago

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Dec 16, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Dec 13, 2024, 6:00 PM EST - 1 year ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Sep 11, 2024, 11:25 PM EDT - 1 year ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Sep 10, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Sep 10, 2024, 7:18 AM EDT - 1 year ago

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Aug 8, 2024, 8:15 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Jun 11, 2024, 8:40 AM EDT - 2 years ago

Viridian Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 6:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Jun 5, 2024, 5:00 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 31, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 15, 2024, 7:35 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Bank of America Health Care Conference 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

Viridian Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 10, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 8, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 7, 2024, 7:33 PM EDT - 2 years ago

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Mar 11, 2024, 2:00 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 5, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Feb 27, 2024, 4:01 PM EST - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 16, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Jan 17, 2024, 10:00 PM EST - 2 years ago

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock